 |
|
HLA-A*2402-restricted URLC10-TTK-KOC1 multipeptide vaccine
A cancer vaccine containing three HLA-A*2402-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from URLC10 (up-regulated lung cancer 10); TTK (TTK protein kinase); and KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-TTK-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK and KOC1 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Previous: | HLA-A*0201-restricted URLC10-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*0201-restricted VEGFR1 peptide vaccine, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted KOC1-TTK-CO16-DEPDC1-MPHOSPH1 multipeptide vaccine, HLA-A*2402-restricted URLC10-KOC1-VEGFR1-VEGFR2 multipeptide vaccine | | Next: | HLA-A*2402-restricted URLC10-TTK-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A*2402-restricted VEGFR1 peptide vaccine, HLA-A*2404-restricted RNF43-TOMM34-VEGFR1-VEGFR2 multipeptide vaccine, HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine, HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine |
|
|
